AIM AIM ImmunoTech

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

OCALA, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that an abstract from the Magee-Womens Research Institute at the University of Pittsburgh School of Medicine (“UPMC") has been accepted for poster presentation at the being held November 1 – 5, 2023 in San Diego, CA and virtually.

The abstract concerns a Phase 2 single arm efficacy/safety trial to evaluate the effectiveness of combining intensive locoregional intraperitoneal (IP) chemoimmunotherapy of cisplatin with AIM’s drug Ampligen and IV infusion of the checkpoint inhibitor pembrolizumab for patients with recurrent platinum-sensitive ovarian cancer. The abstract authors include Robert Edwards, MD, Chief Medical Officer of the UPMC Community and Ambulatory Services Division and Co-Director of the Women’s Cancer Research Center at the UPMC Hillman Cancer Center.

Details for the presentation are as follows:

Abstract Number: 799

Title: Combination intraperitoneal chemoimmunotherapy triggers a T-cell chemotactic locoregional response in patients with recurrent platinum-sensitive ovarian cancer

For more information, please visit the .

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.



For more information, please visit  and connect with the company on , , and .



Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
EN
30/10/2023

Underlying

AIMAIM ImmunoTech

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AIM ImmunoTech

 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering

CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the expected expiration date of the Rights Offering. OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the...

February 12, 2026 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Ev...

AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, February 19th at 4:00 PM ET Event to focus on lead program, Ampligen, for treatment of pancreatic cancer OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced that of AIM, will participate in a  on Thursday, February 19, 2026, at 4:00 PM ET. Equels will focus on AIM’s clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing  in col...

February 12, 2026 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Announces Commencement of Rights Offering

AIM ImmunoTech Announces Commencement of Rights Offering OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced that it has commenced its previously disclosed rights offering (the “Rights Offering”).  Pursuant to the Rights Offering, the Company is distributing to all holders of record of ...

February 11, 2026 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series ...

AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial on Wednesday, February 11th at 1:40 PM EST OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”), today that it will participate in the being held virtually February 10-11, 2026. As part of the event, of AIM, will provide a corporate overview and business outlook and will focus on AIM’s strategic emphasis on pancreatic cancer. Details of the presentation are as follows: Date and Time: Wednesday, February 11, 2026 at 1:40 PM ESTP...

February 6, 2026 1 EN
 PRESS RELEASE
Free
AIM AIM IMMUNOTECH

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress fro...

AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer Year-end report discusses combination therapy’s Mechanism of Action activating both innate and adaptive immune responses OCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today reported positive data in a year-end update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen® (rintatolimod) combined with AstraZenec...

February 5, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch